February 25, 2026

COMING SOON: RaDaR^® ST

We’re excited to introduce the latest from our team of passionate innovators and precision oncology pioneers who have been working tirelessly to develop a molecular residual disease (MRD) test you can rely on to monitor recurrence in your HPV-negative head and neck cancer and HR+/HER2- breast cancer patients. GET TO KNOW RaDaR ST How does it work? RaDaR ST analyzes each patient's unique tumor profile to develop a personalized panel—then uses that panel to detect the presence or absence of circulating tumor DNA in the patient's bloodstream. Why RaDaR ST for MRD testing?   RaDaR ST delivers:   Proven performance with clinical evidence Personalized MRD detection for every patient   Detection as low as 1ppm* Clear reporting for confident decision making   Broad in-network payor contracts Seamless ordering workflows   To learn more about why you should add RaDaR ST to your oncology toolset, visit our website. *Sensitivity demonstrated across four independent analytical and clinical validation studies, with detection down to 1 part per million (ppm) under study-specific conditions. Data on file.

Introducing PanTracer Pro: Now available!

We’re excited to announce that the PanTracer portfolio is expanding with the launch of PanTracer Pro, delivering comprehensive genomic and biomarker insights for therapy selection in one coordinated order. In the evolving landscape of precision oncology, accessing tumor-specific biomarker insights is critical. PanTracer Pro combines comprehensive genomic profiling (CGP) of over 500 cancer-related genes with cancer type-directed ancillary testing, including IHC and HRD scoring, to provide personalized insights for therapy selection. We are proud to introduce PanTracer Pro, the latest addition to the PanTracer family, delivering on our promise of robust, simple solutions for therapy selection. PanTracer Pro reflects NeoGenomics’ ongoing commitment to advancing precision oncology through solutions that empower oncologists and support patient care. For more information on PanTracer Pro, please visit our website.

Better AML Patient Outcomes Are Possible with Express - Now Available in New York State

NeoGenomics’ new AML Express panel supports better outcomes for acute myeloid leukemia (AML) patients with rapid and detailed genetic insights to guide treatment decisions. Its comprehensive NGS-based assessment delivers rapid diagnostic, predictive, or therapeutic information to make informed, personalized treatment decisions. Ensure that your patients receive the most current and effective treatments. Learn more about AML Express.

Expanded MPN NGS Testing Coming Soon to New York State

NeoGenomics is pleased to announce the launch of our myeloproliferative neoplasm (MPN) next-generation sequencing (NGS) testing in New York State, beginning Monday, March 2, 2026. This expansion delivers enhanced analytical sensitivity, broader exon coverage for the JAK2 gene, and a faster turnaround time of 7 days or less for all tests, empowering you with more comprehensive and timely results for patient care. The following MPN NGS assays will be fully validated and available in New York State on Monday, March 2, 2026: MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12–15, CALR, and MPL JAK2 V617F Mutation Analysis by NGS JAK2 Extended (Exon 12–15 nonV617F) Mutation Analysis by NGS CALR Mutation Analysis by NGS MPL Mutation Analysis by NGS The NGS assays will replace the current tests that are performed by PCR, bi-directional sequencing and/or fragment length analysis (FLA). Orders of the old tests will be automatically accessioned for the new tests. Our expanded test menu supports more accurate and efficient detection of clinically actionable mutations, helping guide diagnosis, prognosis, and therapeutic decisions with confidence.  Learn  more. Additionally, please visit  our website to learn our services, call our  dedicated Client Services team at 866.776.5903, option 3, or email us at Client.Services@NeoGenomics.com.  Interface Clients: This test update will involve changes to test names and codes. Please refer to the Interface Updates section for more info.

Coming Soon: PD-L1 22C3 FDA for Ovarian Carcinoma

As a trusted leader in oncology diagnostics, NeoGenomics has delivered reliable PD-L1 testing for years, understanding its critical role in guiding treatment strategies. PD-L1 22C3 FDA for Ovarian Carcinoma will soon be available, advancing our ovarian cancer testing portfolio. PD-L1 22C3 testing integrates into your existing workflows, working alongside comprehensive genomic profiling through our PanTracer Portfolio to give you the most complete picture possible. *NeoTYPE Ovarian Tumor Profile includes PD-L1 LDT; this will be replaced by the companion diagnostic PD-L1 22C3 assay for ovarian carcinoma.

NGS Testing for Patients with Myeloid Disorders

Guidelines recommend next-generation sequencing (NGS) at diagnosis for precise risk stratification, emphasizing its superior diagnostic value and cost-effectiveness compared to single-gene testing.1     Comprehensive NGS testing at diagnosis changes everything for myeloid patients:    Detects 74% more actionable biomarkers   Boosts targeted therapy use by 12%   Cuts non-targeted chemo by 40%2     Neo  Comprehensive® – Myeloid Disorders, a  CGP assay, uses DNA and RNA NGS to detect relevant aberrations for diagnostic  evaluation, prognosis, risk stratification, and therapy guidance for a wide  range of myeloid disorders.  1. Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019 May;104(5):868-871. doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28. PMID: 30923100; PMCID: PMC6518900. 2. Rosenquist R, Bernard E, Erkers T, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413-436.   For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.